Clinical Trial Update: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression [Phase 2]

View source ↗

Summary

This is a Phase 2 frontline study report of brentuximab vedotin combined with CHP for peripheral T-cell lymphoma with low CD30 expression; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-15